Overview

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder
Phase:
Phase 3
Details
Lead Sponsor:
Forest Laboratories
Treatments:
Levomilnacipran
Milnacipran